Replimune Group Inc

NASDAQ REPL

Data sourced from

and

Download Data

Replimune Group Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Replimune Group Inc Working Capital To Sales Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

NASDAQ: REPL

Replimune Group Inc

CEO	Mr. Philip Astley-Sparke FSA
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees	331
Sector	Healthcare
Industry	Biotechnology

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends